On December 24th, 2016, a CCTV reporter's eight-month investigation report video revealed the long-term hidden interest chain in the depth of China's pharmaceutical sales. The high-priced rebates given by medical doctors in hospitals in Shanghai and Hunan provinces were publicly exposed, which caused widespread public concern. In the past few days, the National Health and Family Planning Commission and other relevant regulatory authorities went to Shanghai and Hunan hospitals involved in the investigation to investigate this high-priced medical rebate. Related reading: Doctor rebates in 6 large hospitals in Shanghai and Hunan Under the lens of the unannounced investigation of the investigation, the medical representatives of many well-known pharmaceutical companies entered the public's field of vision. "The people who flashed in the lens (medical representatives) are reported to the Shanghai Municipal Health Planning Commission, the regulatory department, according to this face, Look at which unit, what sales representative, what medicine to sell, and start an inquiry survey." The drug company of the drug rebate incident told the Times Weekly reporter. Pfizer Pharmaceutical Co., Ltd. (hereinafter referred to as "Pfizer"), the head of the Chinese Corporate Communications Department confirmed to the Times Weekly reporter that the company's medical representatives appeared in the lens and accepted the Shanghai Municipal Health Planning Commission. Time Weekly reporter was informed that the Shanghai Municipal Health Planning Commission required the various health planning committees and medical institutions within the jurisdiction to include Lipitor (Atorvastatin Calcium Tablets, Pfizer), Vinodine (Gabapentin, Hainan Seric Pharmaceuticals) and The use of generic drugs was reported and reported, and the use of these drugs in hospitals, departments, and doctors from January to December 2016 was investigated. In fact, a drug from the factory to the dealer, hospital departments, medical representatives and doctors to the hands of patients, has to go through many links, involving a long chain. The multi-level sales link has formed a long chain of interests, and the price of medicines has risen. The Times Weekly reporter found that the drugs of many pharmaceutical companies, including Baiyun Mountain and Hainan Huludao Pharmaceutical Company, were found to be several times higher than the market price. Such a price hurry, was accused of becoming a source of difficulty for the elderly to see a doctor, expensive to see a doctor. Representatives of many pharmaceutical companies enter the mirror In some hospitals in big cities, there are long-term "special patients" who do not see a doctor. They are not only familiar with doctors, but also versatile and can conduct certain transactions with doctors. These "special patients" are medical representatives who sell medicines to doctors in the form of running hospitals every day. Once the interests are formed, doctors can buy medicines after the prescriptions are issued, and medical representatives can get near. 10% commission, and the drug rebates they return to doctors, the proportion is as high as 40%. The Times Weekly reporter noticed that after the drug rebate incident was exposed, it caused great shock in the domestic health care system. In the early morning of December 25, 2016, the website of the National Health and Family Planning Commission issued a letter overnight, saying that it attached great importance to CCTV reports, and immediately asked the health and family planning administrative departments in Shanghai and Hunan to investigate the high-priced rebate incidents and announce the investigation to the public in a timely manner. As a result, the offenders are seriously dealt with according to law. Veterinary Drugs,List of veterinary drugs,effective veterinary drugs SINOCHEM PHARMACEUTICAL CO., LTD , https://www.sinochemnutrition.com
High-priced rebate event fermentation: Pfizer, Baiyun Mountain and other giants were inquired